Karl P Weinrich

20020076382, Jun 20, 2002

Aug 1, 2001

09/920340

Leonard Kaplan - Brookline MA, US
Karl Weinrich - Bridgewater MA, US
Theodore Iorio - Milis MA, US

A61K009/00
A61K031/57

424/043000, 514/179000

A pharmaceutical formulation is provided for pulmonary drug administration of a bronchodilator, a corticosteroid and an optional pharmaceutically acceptable carrier. In addition, methods for using the formulation to treat bronchodilator/corticosteroid-responsive conditions, diseases or disorders are provided, as are drug delivery devices and dosage forms for housing and/or dispensing the formulations.

20040198708, Oct 7, 2004

Apr 14, 2004

10/824711

Leonard Kaplan - Brookline MA, US
Karl Weinrich - Bridgewater MA, US
Theodore Iorio - Millis MA, US

A61K031/573
A61K031/137

514/171000, 514/649000

A pharmaceutical formulation is provided for pulmonary drug administration of a bronchodilator, a corticosteroid and an optional pharmaceutically acceptable carrier. In addition, methods for using the formulation to treat bronchodilator/corticosteroid-responsive conditions, diseases or disorders are provided, as are drug delivery devices and dosage forms for housing and/or dispensing the formulations.

20040235807, Nov 25, 2004

May 21, 2003

10/443672

Karl Weinrich - Bridgewater MA, US
Leonard Kaplan - Brookline MA, US

A61K031/573
A61K031/137

514/171000, 514/649000

A pharmaceutical formulation is provided for nasal drug administration of a topically administrable decongestant, a topically administrable corticosteroid and a pharmaceutically acceptable carrier, and may optionally include further carriers, therapeutic extenders, and the like. Such formulations may also optionally further include a therapeutically active member selected from the group consisting of a topical antibiotic, a topical antihistamine (preferably a non-sedating antihistamine), a leukotriene Dantagonist, a 5-lipoxygenase inhibitor, and a FLAP antagonist, or a pharmaceutically acceptable salt thereof. In addition, methods for using the formulation to treat decongestant/corticosteroids-responsive conditions, diseases or disorders such as chronic obstructive nasal congestion and/or obstructive sleep apnea conditions, are provided, as are drug delivery devices and dosage forms for housing and/or dispensing the formulations.

20050191245, Sep 1, 2005

Feb 27, 2004

10/789965

Christopher Adams - Somerville MA, US
Timothy Maher - Milton MA, US
Karl Weinrich - Bridgewater MA, US

A61L009/04
A61K009/14

424045000, 424046000

Pharmaceutical compositions useful for the treatment of cardiovascular disorders such as hypertension are described. These compositions are formulated for nasal administration and comprise a therapeutically effective amount of a calcium channel blocker, optionally a pharmaceutically acceptable carrier that is suitable for nasal administration, and one or more optional members selected from excipients and additional pharmaceutically active agents.

20070134277, Jun 14, 2007

Dec 9, 2005

11/297639

Wen Chen - Woburn MA, US
Michael Shannon - Brookline MA, US
Vimonrat Umprain - Sharon MA, US
Karl Weinrich - Bridgewater MA, US

Children's Medical Center Corporation - Boston MA

A61K 9/00
A61K 31/198

424400000, 514562000

The pharmaceutical formulations of the invention for masking the odor from the sulfur-containing active agent comprise at least one sulfur-containing active agent, an effective amount of at least one flavoring agent. Any flavoring agent or combinations of flavoring agents may be used in the pharmaceutical formulation of the invention. The flavoring agent may be natural flavors, natural fruit flavors, artificial flavors, and mixtures thereof. The pharmaceutical formulation may contain an artificial sweetener, a natural sweetener or mixtures thereof. The pharmaceutical formulations are provided in liquid dosage form or a dry powder dosage form for reconstitution in water. Stabilizer added as one of expicients can extend the stability of the pharmaceutical formulation liquid dosage form for a period of at least 30 days when the formulation is stored below room temperature. The pharmaceutical formulations of the invention are palatable and particularly useful for the administration of sulfur-containing drugs to very small children that are in need of such medications. Methods of forming a liquid dosage form of pharmaceutical formulation by adding water to the dry powder form, methods to prepare an odor-masking pharmaceutical formulation and methods for treating lead poisoning or Wilson's disease using the odor-masking pharmaceutical formulation are also provided.

20090117056, May 7, 2009

Sep 27, 2006

11/528893

Karl P. Weinrich - Bridgewater MA, US

Little Calumet Holdings, LLC - Silver Spring MD

A61K 35/74
A61K 9/68
A61P 1/14

424 48, 424 9345, 424 9346, 424 9344

Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar alcohols mannitol, sorbitol, and lactitol, and/or phytonutrients such as oligomeric proanthocyanidins (OPCs). The probiotic compositions may be formulated into oral dosage forms such as tablets, caplets, and capsules, or manufactured as a chewing gum or as a powder formulation that may be dissolved in a liquid such as water, milk, juice, or yogurt.

D3571211, Apr 11, 1995

Dec 27, 1991

7/817125

Manuel A. Fuentes - Queretaro, Qro. C.P. 76000, MX
Raymundo Vargas - Mexico D.F. 03100, MX
Karl P. Weinrich - Stony Point NY

D 4104